Cargando…
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be...
Autores principales: | Debarri, Houria, Lebon, Delphine, Roumier, Christophe, Cheok, Meyling, Marceau-Renaut, Alice, Nibourel, Olivier, Geffroy, Sandrine, Helevaut, Nathalie, Rousselot, Philippe, Gruson, Bérengère, Gardin, Claude, Chretien, Marie-Lorraine, Sebda, Shéhérazade, Figeac, Martin, Berthon, Céline, Quesnel, Bruno, Boissel, Nicolas, Castaigne, Sylvie, Dombret, Hervé, Renneville, Aline, Preudhomme, Claude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747230/ https://www.ncbi.nlm.nih.gov/pubmed/26486081 |
Ejemplares similares
-
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2015) -
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
por: Ferret, Yann, et al.
Publicado: (2018) -
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020) -
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
por: Renneville, Aline, et al.
Publicado: (2014) -
Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
por: Boyer, Thomas, et al.
Publicado: (2019)